FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy

  • November 16, 2026

  • 3 min

Share

Clinical Report: FDA Investigates Malignancy Risk Linked to Zolgensma

Overview

The FDA is investigating postmarketing reports of tumors after Zolgensma treatment, including two tumors in which molecular testing identified integration of the therapy’s AAV vector DNA near or within the oncogene GLI1. The agency says the potential risk also applies to Itvisma, which uses the same vector and genetic construct, and is assessing whether prescribing information or long-term follow-up requirements should change. The FDA states that the benefits of both approved therapies continue to outweigh their potential risks and advises monitoring for tumor formation.

Background

Zolgensma (onasemnogene abeparvovec) delivers a functional copy of SMN1 using an AAV9 vector to treat spinal muscular atrophy. Recombinant AAV DNA generally persists outside chromosomes, although rare integration into the host genome can occur; current U.S. prescribing information describes tumorigenicity from integration as a theoretical risk. Zolgensma is administered intravenously and is approved in the United States for children younger than two years, while intrathecal Itvisma was approved in November 2025 for patients aged two years and older. The FDA’s investigation also has relevance to other AAV-based programs, citing published integration-associated oncogenesis cases involving investigational therapies.

Data Highlights

MeasureReported information
Postmarketing tumor reportsNovartis reported nine tumors among more than 6,000 patients treated with Zolgensma since its 2019 approval.
GLI1-associated casesThree cases involved abnormal GLI1 activity; vector DNA integration was identified in two, with the therapy’s promoter positioned upstream of or within GLI1.
Itvisma reportsNo tumors had been reported following Itvisma treatment at the time described.
Other AAV programs cited by FDATwo published integration-associated oncogenesis cases involved investigational programs: one near GLI1 after FBX-101 and one involving PLAG1 after RGX-111.

Key Findings

  • The FDA received postmarketing reports of tumors involving the central and peripheral nervous systems, spinal and paraspinal regions, and kidney after Zolgensma treatment.
  • Three reported cases involved abnormal GLI1 activity; in two, molecular analysis found Zolgensma vector DNA integrated into the patient’s genome near or within GLI1.
  • Novartis reported nine tumor cases among more than 6,000 Zolgensma-treated patients, with evidence of vector integration in two cases. The company said both patients received tumor treatment and remain under monitoring.
  • The FDA considers the potential neoplasia risk applicable to Itvisma because it contains the same vector and genetic construct; no tumors following Itvisma treatment had been reported in the source material.
  • The FDA is monitoring similar AAV therapies and evaluating whether Zolgensma and Itvisma prescribing information or long-term follow-up requirements need changes. Novartis is conducting long-term safety studies.
  • The FDA advises monitoring patients and clinical trial participants receiving either product for tumor formation and states that the benefits of both approved therapies continue to outweigh their potential risks.

Clinical Implications

The FDA advises clinicians to monitor patients receiving Zolgensma or Itvisma for tumor formation; the agency is evaluating whether additional changes to product labeling or long-term follow-up requirements are warranted. For the two patients with vector integration described by Novartis, the company reported that tumors were treated and monitoring continues.

Conclusion

The FDA’s investigation links two reported tumors to integration of Zolgensma vector DNA near or within GLI1, while the mechanism in a third GLI1-associated case remains under investigation. The agency is continuing to assess the signal and advises tumor monitoring for recipients of both Zolgensma and Itvisma.

Related Resources & Content

  1. U.S. Food and Drug Administration, FDA Safety and Availability Communication, 2026 — FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
  2. Novartis, company statement shared by SMA Europe, year not specified — Tumor reports among Zolgensma-treated patients
  3. Daniel J. Benedetti and Jonathan M. Marron, ASCO Publications, 2026 — Gene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism
  4. The Medicine Maker, 2023 — The FDA Investigates T-Cell Malignancies in CAR-T Therapy
  5. the medicine maker — This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
  6. Associated Press Health — FDA adds strongest warning to Sarepta gene therapy
  7. FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
  8. Gene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism
  9. The FDA Investigates T-Cell Malignancies in CAR-T Therapy
  10. Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study.
  11. Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

Original Source(s)

Related Content